Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 103.41% | 126.61% | 139.98% | 51.87% | 85.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 103.41% | 126.61% | 139.98% | 51.87% | 85.55% |
| Cost of Revenue | 3,363.72% | -57.57% | 113.47% | -28.63% | -96.80% |
| Gross Profit | 93.64% | 142.73% | 141.73% | 57.99% | 123.77% |
| SG&A Expenses | 21.60% | 27.12% | 24.20% | 17.77% | 23.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.93% | -4.52% | -2.34% | -6.70% | -6.11% |
| Operating Income | 60.80% | 62.03% | 66.37% | 36.54% | 29.83% |
| Income Before Tax | 55.54% | 58.06% | 62.37% | 169.22% | 29.66% |
| Income Tax Expenses | 1,001.64% | 38.58% | -46.32% | -65.38% | -94.11% |
| Earnings from Continuing Operations | 54.96% | 57.91% | 62.35% | 168.80% | 30.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.96% | 57.91% | 62.35% | 168.80% | 30.09% |
| EBIT | 60.80% | 62.03% | 66.37% | 36.54% | 29.83% |
| EBITDA | 64.08% | 64.23% | 68.31% | 38.59% | 27.46% |
| EPS Basic | 56.88% | 59.70% | 63.75% | 167.18% | 31.25% |
| Normalized Basic EPS | 45.80% | 59.84% | 63.76% | 36.18% | 20.44% |
| EPS Diluted | 56.88% | 59.70% | 63.54% | 164.97% | 31.25% |
| Normalized Diluted EPS | 45.80% | 59.84% | 63.76% | 38.40% | 20.44% |
| Average Basic Shares Outstanding | 4.45% | 4.44% | 3.86% | 2.42% | 1.70% |
| Average Diluted Shares Outstanding | 4.45% | 4.44% | 3.86% | 6.11% | 1.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |